Boehringer Ingelheim Deal With Pfizer Closes

Boehringer Ingelheim Deal With Pfizer Closes

German company now a major player in animal health, vaccines.

Boehringer Ingelheim VetMedica Inc. has closed a deal with Pfizer that gives the German company a major portion of the Fort Dodge Animal Health Business.

Boehringer Ingelheim, which has its American headquarters in St. Joseph, Mo., will get number of Fort Dodge products as well as two manufacturing and research facilities in Fort Dodge, Iowa.

The acquisition significantly increases the size of Boehringer Ingelheim's companion animal and cattle portfolios and gives the company new importance in the world of vaccine supplies.

"We'll be expanding our business significantly, in fact, doubling our sales in the United States," said George Heidgerken, BIVI president.

The cattle vaccines included in the acquisition include the Triangle, Pyramid and Presponse vaccine lines. Pharmaceutical products being acquired include Cydectin (moxidectin) for cattle and sheep as well as Polyflex (ampicillin sodium). The dairy portfolio includes the key brands Today and Tomorrow.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.